The Utility of PET/Computed Tomography for Radiation Oncology Planning, Surveillance, and Prognosis Prediction of Gastrointestinal Tumors.

The Utility of PET/Computed Tomography for Radiation Oncology Planning, Surveillance, and Prognosis Prediction of Gastrointestinal Tumors. PET Clin. 2020 Jan;15(1):77-87 Authors: Rice SR, Chuong M, Koroulakis A, Siddiqui OM, Sharma AM, Simone CB, Molitoris JK, Kaiser A Abstract At present, the strongest evidence for the use of PET/computed tomography (CT) in gastrointestinal (GI) malignancies is to rule out distant metastatic disease at diagnosis, radiation treatment planning for anal malignancies, and disease recurrence monitoring in colorectal and anal malignancies. Use of PET/CT for GI malignancies continues to evolve over time, with new studies evaluating prognostic abilities of PET/CT and with increasing sensitivity and spatial resolution of more modern PET/CT scanners. The authors encourage future applications and prospective evaluation of the use of PET/CT in the staging, prognostication, and recurrence prediction for GI malignancies. PMID: 31735304 [PubMed - in process]
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: PET Clin Source Type: research

Related Links:

ConclusionLong after pelvic radiotherapy, symptomatic subcutaneous macrocalcification is suggestive of radiation-induced calcinosis. Prolonged antibiotic therapy followed by PENTOCLO treatment led to clinical improvement.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
ConclusionWe believe that mesenteric defects should be closed after laparoscopic resection of the left side of transverse colon, regardless of their size.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Authors: Bekir Hacioglu M, Kostek O, Kurt N, Kucukarda A, Gokyer A, Ustabasioglu FE, Karatas F, Tuncbilek N, Uzunoglu S, Bilici A, Cicin I, Erdogan B Abstract PURPOSE: To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments and prognostic significance in the patients with metastatic colorectal cancer (mCRC). METHODS: A total of 36 mCRC patients, who received regorafenib or TAS-102 in the third-line and subsequent settings were assessed in the analysis. S...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Conclusions: The finding of advanced colonic neoplasia in follow-up colonoscopy after an acute episode of CT-proven diverticulitis is equivalent to, or less than, that of the population colorectal cancer screening program. Routine colonoscopy is not necessary unless there are other concerning symptoms/CT findings.
Source: Surgical Laparoscopy, Endoscopy and Percutaneous Techniques - Category: Surgery Tags: Original Articles Source Type: research
Conclusion: Radiomics analysis of iodine-based MD images with DECT imaging holds great potential to predict MSI status in CRC patients.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Benefits of 5-year survivals after pulmonary metastasectomy of colorectal carcinoma range from 21% - 62%. Selection criteria were completely resectable lesions in the lung, lesions
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Thoracic surgery Source Type: research
ConclusionTreatment decisions must be individualized, and depend on the presence of systemic disease. Selected patients may benefit from resection of metastases, and PET scan may be useful to identify patients who will benefit from resection.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
We report the case of a Lynch syndrome patient with metastatic CRC and urothelial cancer who was treated sequentially with pembrolizumab (targeting PD1), atezolizumab (targeting PD‐L1), brief rechallenge with pembrolizumab, and finally the combination of ipilimumab (targeting CTLA‐4) and nivolumab (targeting PD1). Over a 28‐month period the patient experienced prolonged disease control with each different regimen the first time it was given, including metabolic response by positron emission tomography and computed tomography scanning and tumor marker reductions. The case suggests that some patients with advanced MMR...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Precision Medicine Clinic: Molecular Tumor Board, Gastrointestinal Cancer Precision Medicine Clinic: Molecular Tumor Boards Source Type: research
ConclusionTumor uptake on [89Zr]Zr-cetuximab PET/CT failed to predict treatment benefit in patients withRAS wild-type mCRC receiving cetuximab monotherapy.BRAF mutations, right-sidedness, and low sEGFR correlated with intrinsic resistance to cetuximab.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
ConclusionThis relatively small series suggest that even a sufficient omentoplasty, as determined by postoperative imaging, does not reduce pelviperineal morbidity after APR for rectal cancer. The methodology of CT-based assessment of an omentoplasty as well as the correlation with postoperative outcomes has to be validated in future studies.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | CT Scan | Gastroenterology | PET Scan | Study